New drug aims to supercharge immune system against HPV throat cancer
NCT ID NCT04852328
First seen Jun 27, 2026 · Last updated Jul 21, 2026 · Updated 2 times
Summary
This study tests an experimental drug called CUE-101 in 30 people with HPV16-positive throat cancer. The drug is given before standard treatments like surgery or chemoradiation to see if it safely boosts the body's immune cells to fight the cancer. Researchers will monitor side effects and measure immune responses in blood and tumor samples.
This is an AI summary of the original study and may miss details. Read our disclaimer.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for HPV16-POSITIVE OROPHARYNGEAL SQUAMOUS-CELL CARCINOMA are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Study contacts
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
Locations
-
Washington University School of Medicine
RECRUITINGSt Louis, Missouri, 63110, United States
Contact
Contact
Contact
Contact
Contact
Contact
Contact
Contact
Contact
Contact Phone: •••-•••-•••• Email: •••••@•••••
Contact
Contact
Contact
Contact
Contact
Contact
Contact
Contact
Contact
Contact
Contact
More trials for these conditions
Other studies related to the condition(s) this trial covers.
- Can a simple swab predict who needs less radiation?
- New drug combo aims to shrink oral cancers before surgery
- Acupuncture timing may be key to preventing dry mouth in head and neck cancer patients
- New Vaccine-Drug combo aims to tame HPV throat cancer with less radiation
- New pill-chemo combo takes on hard-to-treat cancers
- HIV and oral cancer: what blocks access to care?